Clinical Practice Guidelines (CPG)1. Management of Metastatic Humeral Disease
From the document: This clinical practice guideline for the surgical management of metastatic humeral disease is based on a systematic review of published studies surrounding the management of metastatic disease, multiple myeloma, and lymphoma limited to the humerus. In addition to providing practice recommendations, this guideline also highlights both limitations in the literature and consequent areas that should be the focus of future research collaborations. Read CPG Metastatic Humerus Document 2. Treatment of Metastatic Carcinoma and Myeloma of the Femur
This MSTS-led guideline was produced in collaboration with ASCO and ASTRO. From the document: Previous guidelines that address the potential benefits of bone targeted agents (e.g. bisphosphonates) refer to reductions in skeletal related events (SREs). This is a broad term that encompasses pathologic fractures of any bone, need for surgery or radiation, and hypercalcemia. Guidelines around the use of palliative radiotherapy have been primarily focused on short-term pain control and long-term radiation-induced side effects, without significant consideration to modifying the risk of pathologic fracture or the need for subsequent surgical intervention ... The purpose of this clinical practice guideline is to provide medical, radiation, and surgical providers with a practical and vetted set of recommendations regarding the management of patients with metastatic or myelomatous lesions of the femur
|